China Oncology Drugs Market - Forecast(2024 - 2030)

1. China Oncology Drugs Market Overview

2. China Oncology Drugs Market Executive Summary

3. China Oncology Drugs Market Landscape

3.1. Market Share Analysis

3.2. Comparative Analysis 

3.2.1. Product Benchmarking

3.2.2. End User profiling

3.2.3. Patent Analysis

4. China Oncology Drugs Market Forces

4.1. Market Drivers

4.2. Market Constraints & Challenges

4.3. Attractiveness of the Industry

4.3.1. Power of Suppliers

4.3.2. Power of Customers

4.3.3. Threat of New entrants

4.3.4. Threat of Substitution

4.3.5. Degree of Competition

5. China Oncology Drugs Market Strategic Analysis

5.1. Value Chain Analysis

5.2. Opportunities Analysis

5.3. Market Life Cycle Analysis

6. China Oncology Drugs Market – By Therapy

6.1. Introduction

6.2. Chemotherapy

6.3. Targeted Therapy

6.4. Immunotherapy (Biologics Therapy)

6.4.1.  Monoclonal Antibodies 

6.4.2. Cancer Growth Inhibitors

6.4.3. Angiogenesis Inhibitors 

6.4.4. Gene Therapy

6.4.5. Others

6.5. Hormonal Therapy

6.6. Others

7. China Oncology Drugs Market – By Type of Cancer

7.1. Introduction

7.2. Blood Cancer

7.2.1. Leukemia

7.2.2. Hodgkin Lymphoma (HL)

7.2.3. Non-Hodgkin Lymphoma (NHL)

7.2.4. Multiple Myeloma

7.3. Breast Cancer

7.3.1. In Situ Cancers

7.3.2. Invasive (Infiltrating) Breast Cancer

7.3.3. Others

7.4. Intestinal Cancer

7.4.1. Adenocarcinomas

7.4.2. Sarcoma

7.4.3. Gastrointestinal Stromal Tumors

7.4.4. Carcinoid

7.4.5. Others

7.5. Prostate Cancer

7.6. Respiratory/Lung cancer

7.6.1. Small Cell Lung Cancer

7.6.2. Non-Small Cell Lung Cancer

7.7. Cervical Cancer

7.7.1. Squamous Cell Carcinomas

7.7.2. Adenocarcinomas

7.7.3. Others

7.8. Skin Cancer

7.8.1. Melanoma

7.8.2. Non-Melanoma

7.9. Bone Cancer

7.9.1. Osteosarcoma

7.9.2. Chondrosarcoma

7.9.3. Chordoma

7.9.4. Ewing Tumor

7.9.5. Giant Cell Tumor of Bone

7.9.6. Fibrosarcoma and Malignant Fibrous Histiocytoma

7.9.7. Others

7.10. Colorectal Cancer

7.10.1. Adenocarcinomas

7.10.2. Carcinoids

7.10.3. Others

7.11. Kidney Cancer

7.11.1. Renal Cell Carcinoma

7.11.2. Urothelial Carcinoma

7.11.3. Sarcoma

7.11.4. Wilms Tumor

7.11.5. Others

7.12. Pancreatic Cancer

7.12.1. Exocrine Tumors

7.12.2. Endocrine Tumors

7.13. Ovarian Cancer

7.13.1. Epithelial Tumors

7.13.2. Germ Cell Carcinoma Tumors

7.13.3. Stromal Carcinoma Tumors

7.13.4. Others

7.14. Bladder Cancer

7.14.1. Urothelial Carcinoma

7.14.2. Squamous Cell Carcinoma

7.14.3. Adenocarcinoma

7.14.4. Others

7.15. Thyroid Cancer

7.15.1. Papillary Carcinoma

7.15.2. Follicular Carcinoma

7.15.3. Hurthle Cell Carcinoma

7.15.4. Medullary Thyroid Carcinoma

7.15.5. Anaplastic Carcinoma

7.16.  Brain Cancer

7.17. Liver Cancer

7.17.1. Hepatocellular Carcinoma (HCC)

7.17.2. Fibrolamellar HCC

7.17.3. Cholangiocarcinoma

7.17.4. Angiosarcoma

7.17.5. Secondary Liver Cancer

7.18. Uterine Cancer

7.18.1. Endometrial Cancer

7.18.2. Uterine Sarcoma

7.19. Others

8. China Oncology Drugs Market Entropy

9. China Oncology Drugs Market Company Profiles

9.1. F. Hoffmann-La Roche AG

9.2. Celgene Corporation

9.3. Bristol-Myers Squibb Company

9.4. GlaxoSmithKline plc

9.5. Pfizer Inc.

9.6. Company 6

9.7. Company 7

9.8. Company 8

9.9. Company 9

9.10. Company 10

*More than 10 Companies are profiled in this Research Report*

"*Financials would be provided on a best efforts basis for private companies"

10. Appendix

10.1. Abbreviations

10.2. Sources

10.3. Research Methodology

10.4. Bibliography

10.5. Compilation of Expert Insights